AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
Lausanne, Switzerland, July 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announces three presentations at the Alzheimer's Association International Conference® 2026, taking place July 12-15 in London, UK.
Across these AAIC presentations, we are showing how AC Immune's Morphomer®-based small molecule approach has generated differentiated therapeutic and imaging assets. Our first-in-class TDP-43 PET tracer has generated encouraging early human imaging data in FTD and ALS; our novel brain-penetrant NLRP3 inhibitor is in Phase 1 with a profile supporting an orally delivered CNS therapy; and our alpha-synuclein Morphomer® program demonstrates potent, brain-penetrant inhibition of pathology with in vivo neuroprotective effects. Together, these data reinforce the opportunity to build biomarker-led therapeutic programs for major neurodegenerative diseases.
Oral Presentation
Discovery and initial clinical evaluation of [18F]ACI-19626, a first-in-class TDP-43 PET tracer
Presenter: Dr. Tamara Seredinina
Session: Developing Topics in ADRD Diagnostics
Date/Time: July 15, 8:00 – 8:45 AM BST (GMT+1)
Location: Hall S11
Poster Presentations
Novel potent brain penetrant NLRP3 inhibitor ACI-19764 demonstrates efficacy in models of neuroinflammation
Presenter: Dr. Chantal Bazenet
Session: Drug Development, Human
Date/Time: July 12, 7:30 AM – 4:15 PM BST (GMT+1)
Location: Exhibit Hall (# Sunday-0177)
Development of an aggregation inhibitor targeting alpha-synuclein pathology
Presenter: Dr. Francesca Capotosti
Session: Drug Development, Nonhuman
Date/Time: July 14, 7:30 AM – 4:15 PM BST (GMT+1)
Location: Exhibit Hall (# Tuesday-0074)
For further information, please contact:
SVP, Investor Relations & Corporate Communications | International Media |
About AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and NeuroOrphan indications driven by misfolded proteins. The Company's two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its pipeline of first- and best-in-class assets, which currently features a range of therapeutic and diagnostic programs, including candidates in Phase 2 and Phase 3 development. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties.